GVAG
XBIO icon

Great Valley Advisor Group’s Xenetic Biosciences XBIO Stock Holding History

Great Valley Advisor Group’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,060
Closed -$4.3K – 749
2023
Q1 		$4.3K Hold
1,060
– – ﹤0.01% 695
2022
Q4 		$3.02K Hold
1,060
– – ﹤0.01% 695
2022
Q3 		$6K Hold
1,060
– – ﹤0.01% 670
2022
Q2 		$8K Buy
+1,060
New +$8.57K ﹤0.01% 671

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.15B AUM 24.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Great Valley Advisor Group's XBIO Position: Q2 2023 in Review

Great Valley Advisor Group sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 1,060 shares — an estimated $4.3K sold.

Great Valley Advisor Group first reported a position in XBIO in Q2 2022 and held it in 4 quarters. The position peaked at $8K in Q2 2022. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

  • Great Valley Advisor Group reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
  • Great Valley Advisor Group sold 1,060 Xenetic Biosciences shares in Q2 2023, an estimated $4.3K.
  • Great Valley Advisor Group first reported a position in Xenetic Biosciences in Q2 2022 and held it in 4 quarters.
  • Great Valley Advisor Group's Xenetic Biosciences position peaked at $8K in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on Great Valley Advisor Group's 13F filing for Q2 2023, filed 10 Aug 2023.